Skip to main content

Table 2 Selected characteristics of patients at start of follow-up, by analysis cohort

From: Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries

  New-user cohort Newly-discontinued-user cohort
Discontinued cinacalcet Did not discontinue Reinitiated cinacalcet Did not reinitiate
N 172 441 171 244
Age (yrs) 62.8 (16.9) 61.9 (15.6) 63.6 (14.8) 63.5 (15.8)
Time on dialysis (yrs) [median/IQR] 3.9 [1.8, 7.1] 3.7 [1.7, 7.0] 5.1 [2.7, 9.6] 4.5 [2.4, 8.5]
Male (%) 60.5 62.1 52.0 58.9
Coronary artery disease (%) 31.6 26.1 28.2 32.9
Cancer (%) 16.4 11.7 14.8 12.6
Other cardiovascular disease (%) 24.0 27.1 25.9 28.9
Cerebrovascular disease (%) 16.5 11.2 13.6 14.2
Congestive heart failure (%) 15.8 12.2 12.9 15.5
Diabetes (%) 28.7 29.6 27.8 31.1
GI Bleeding (%) 2.9 3.4 4.1 5.0
Hypertension (%) 86.5 88.5 87.6 86.3
Lung disease (%) 16.5 11.9 9.5 15.5
Psychiatric disorder (%) 21.6 11.5 17.1 21.8
Peripheral vascular disease (%) 31.6 24.8 27.6 30.1
Hospitalized in baseline period (%) 18.0 16.1 15.8 18.7
BMI (kg/m2) 25.9 (5.3) 26.5 (5.2) 26.2 (5.3) 26.2 (5.4)
Serum phosphorus (mg/dl) 5.3 (1.7) 5.4 (1.5) 5.1 (1.7) 5.1 (1.6)
Serum PTH (pg/ml) [median/IQR] 430 [317, 749] 507 [340, 780] 310 [145, 575] 237 [117, 518]
Serum total calcium (mg/dl) 9.1 (0.9) 9.3 (0.8) 9.0 (0.9) 8.9 (0.8)
Serum albumin (g/dl) 3.8 (0.4) 3.8 (0.5) 3.8 (0.5) 3.7 (0.5)
Phosphate binder use (%)
 No phosphate binder use 17.5 15.8 15.5 18.0
 Ca-containing only 7.0 12.3 13.1 11.7
 Non-Ca-containing only 57.9 53.3 54.2 49.4
 Both 17.5 18.6 17.3 20.9
Vitamin D (active/analog) use (%)
 No vitamin D use 42.9 37.5 34.5 42.3
 IV vitamin D only 29.4 30.1 31.6 27.2
 Oral vitamin D only 25.9 32.4 32.1 29.3
 Both 1.8 0.0 1.8 1.3
  1. New-user cohort patients required at least 3 consecutive months without cinacalcet prescription prior to starting cinacalcet. Newly-discontinued-user cohort patients required at least 3 consecutive months with cinacalcet prescription prior to discontinuing cinacalcet. Values represent mean (standard error) unless noted otherwise. Comorbidities were measured at DOPPS study entry; all other values were measured at the end of the baseline period prior to the start of follow-up for each cohort. Psychiatric disorder includes depression, bipolar disorder, schizophrenia, and alcohol or substance abuse